English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/61003
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

AuthorsStadtmauer, Edward A.; San Miguel, Jesús F.
Issue Date2009
PublisherJohn Wiley & Sons
CitationEuropean Journal of Haematology 82(6): 426-432 (2009)
AbstractThis subset analysis of data from two phase III studies in patients with relapsed or refractory multiple myeloma (MM) evaluated the benefit of initiating lenalidomide plus dexamethasone at first relapse. Multivariate analysis showed that fewer prior therapies, along with β2-microglobulin (≤2.5 mg/L), predicted a better time to progression (TTP; study end-point) with lenalidomide plus dexamethasone treatment. Patients with one prior therapy showed a significant improvement in benefit after first relapse compared with those who received two or more therapies. Patients with one prior therapy had significantly prolonged median TTP (17.1 vs. 10.6 months; P = 0.026) and progression-free survival (14.1 vs. 9.5 months, P = 0.047) compared with patients treated in later lines. Overall response rates were higher (66.9% vs. 56.8%, P = 0.06), and the complete response plus very good partial response rate was significantly higher in first relapse (39.8% vs. 27.7%, P = 0.025). Importantly, overall survival was significantly prolonged for patients treated with lenalidomide plus dexamethasone with one prior therapy, compared with patients treated later in salvage (median of 42.0 vs. 35.8 months, P = 0.041), with no differences in toxicity, dose reductions, or discontinuations despite longer treatment. Therefore, lenalidomide plus dexamethasone is both effective and tolerable for second-line MM therapy and the data suggest that the greatest benefit occurs with earlier use.
DescriptionRe-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5.-- et al.
URIhttp://hdl.handle.net/10261/61003
DOI10.1111/j.1600-0609.2009.01257.x
Identifiersdoi: 10.1111/j.1600-0609.2009.01257.x
issn: 0902-4441
e-issn: 1600-0609
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Lenalidomide in combination.pdf168,45 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.